Mitomycin C in the chemotherapy of advanced breast cancer

Seminars in Oncology

Volumn 15, Issue 3 SUPPL. 4, 1988, Pages 74-79

  Garewal, Harinder S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; VINBLASTINE;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; HUMAN; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMAN; MITOMYCIN; MITOMYCINS;

EID: 0023811682     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Cancer Statistics
2. Mitomycin C: A review
3. The chemical therapy of breast cancer
4. Cancer of the breast: The past decade
5. Phase II study of vindesine in patients with advanced breast cancer
6. Phase II study of vindesine in patients with metastatic breast cancer
7. Dihydroxyanthracenedione: A promising new drug in the treatment of metastatic breast cancer
8. Bisantrene, an active new drug in the treatment of metastatic breast cancer
9. Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy
10. A randomized trial of Adriamycin ν mitomycin at low doses in CMF refractory breast cancer patients
11. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy
12. Mitomycin C in large infrequent doses in breast cancer
13. Mitomycin C and vinblastine chemotherapy for advanced breast cancer
14. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine
15. Mitomycin C (M) and vinblastine (V) in the treatment of advanced breast cancer
16. Mitomycin C and vinblastine in the treatment of advanced breast cancer
17. Phase II study of vincristine, mitomycin C and mitoxantrone in advanced breast cancer: A preliminary report of response and toxicity
18. 5-Fluorouracil and mitomycin C in advanced breast cancer
19. Vindesine and mitomycin C in chemotherapy refractory advanced breast cancer
20. Mitomycin C (MMC) and Velban (VLB) as fourth-line chemotherapy in metastatic breast cancer: A pilot trial
21. Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer
22. Vincristine, doxorubicin, and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, and fluorouracil (CMF): A clinical trial of the Piedmont Oncology Association (POA)
23. Vincristine, Adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report
24. 5-Fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM): An effective program for breast cancer, even for disease refractory to previous chemotherapy. A Northern California Oncology Group (NCOG) Study
25. Combination doxorubicin-mitomycin therapy for hormonal and CMF-refractory metastatic breast cancer
26. Treatment of advanced breast cancer with two doxorubicin-containing regimens
27. Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma
28. DAV (dibromodulcitol, Adriamycin, vincristine) ν MAV (mitomycin C, Adriamycin, vincristine) in advanced breast cancer
29. Mitomycin, doxorubicin and vinblastine as second-line chemotherapy in patients with advanced breast cancer
30. Adriamycin vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer
31. Response and survival in advanced breast cancer after two non-cross-resistant combinations
32. Chemotherapy of disseminated breast cancer: Current status and prospects
33. A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy
34. A controlled study in the use of combined drug therapy for metastatic breast cancer
35. Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG
36. Combination chemotherapy for advanced breast cancer utilizing vincristine, Adriamycin, and cyclophosphamide (VAC)
37. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: A randomized trial
38. Rationale for the use of alternating non-cross-resistant chemotherapy
39. Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross-resistant chemotherapy regimens
40. Mitomycin: Ten years after approval for marketing